Qualigen Therapeutics Extends Research Agreement on RAS Program

Qualigen Therapeutics, Inc. recently announced the mutual extension of a research agreement with University of Louisville Research Foundation (ULRF). The revised agreement expands the company’s collaboration with the research institution to develop its ongoing RAS-F platform currently in the discovery stage for solid tumors through Q1 of 2023.

“This extension of our agreement with ULRF represents our continued commitment to develop our exciting RAS-F platform by leveraging the ongoing relationship with this prestigious research institution,” said Michael Poirier, Qualigen’s CEO. “We are both proud to be associated with ULRF and confident that our further collaboration may serve to identify the lead candidate for IND-enabling studies by late 2022.”

Geoffrey Clark, PhD, Professor of Pharmacology and Toxicology at University of Louisville (UofL), added “The partnership with Qualigen Therapeutics has been very important to us. The expanded agreement gives our team the opportunity to generate and select additional compounds, fully explore mechanisms within the RAS pathway, and drive the program towards a lead clinical candidate.”

Mutant RAS is the most common cancer oncogene, present in one quarter of all cancers. It acts as a “hub” that activates multiple effector pathways to promote cancer growth. Targeting the downstream PI3K-AKT and RAF-MEK-ERK signaling pathways has been a promising therapeutic approach to date. However, approved therapeutic options are limited to cancers exhibiting specific RAS mutations, such as KRAS G12C. Exploring additional downstream effectors of the RAS pathway such as the RAL GTPase family are areas of active research as there are no FDA-approved pan-mutational RAS protein inhibitors.

Qualigen’s RAS-F program is a family of small molecules designed to prevent mutated RAS gene proteins from binding to their effector proteins. Exclusively in-licensed from UofL, compounds from this discovery engine have been shown to inhibit a broad range of RAS mutations and are active against the growth of multiple in vivo tumor models. Qualigen is evaluating promising compounds generated from this partnership in various RAS-driven advanced solid tumors such as pancreatic, colorectal and lung cancers.

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for cancer, as well as maintaining and expanding its core FDA-cleared FastPack System, which has been used successfully in diagnostics for over 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). The investigational compounds within Qualigen’s RAS-F family of RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information, visit www.qualigeninc.com.